PDSB News and Press, PDS Biotechnology Corporation From 06/08/21

Clover Health Investments (CLOV) +37%.Aytu Biopharma (AYTU) +20%.NextDecade Corporation NEXT +20% after Morgan Stanley upgrades on Rio Grande LNG outlook.Cyclerion Therapeutics (CYCN) +16%.The Wendy's (WEN) +16%.Stitch Fix SFIX +14% on Q3 results.PDS Biotechnology PDS...

FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by PDS Biotechnology Corporation (Nasdaq: PDSB), we've been informed by the company, the beginning of the conference call paragraph should read "The company is host...

PDS Biotechnology (PDSB) presents interim data from Phase 2 trial studying PDS0101 (Versamune-HPV16) in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824) and NHS-IL12 (M9241) in both checkpoint inhibitor naïve and refractory patients with advance...

FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the presentati...

FLORHAM PARK, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the Compa...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Meme stocks will be watched closely again with some investors still looking for an easy ride. As part of a heat check on...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

PDSB has gained over 125% since clinical data in an ASCO abstract on its lead cancer therapeutic was published. The company still has lots of room for growth if its lead therapeutic candidate is eventually approved to treat HPV-associated cancers. Competition for therapeutics for ...

PDS Biotechnology ([[PDSB]] -3.3%) announces the protocol amendment to expand its Phase 2 VERSATILE-002 study to include patients, in an additional arm, who have failed prior checkpoint inhibitor ((CPI)) therapy (CPI refractory patients).The study is designed to evaluate PDS0101 in combi...

FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...